Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Thermo Fisher Scientific Inc Stock Research

TMO

499.49USD+3.70(+0.75%)Market Closed
Watchlist

Market Summary

USD499.49+3.70
Market Closed
0.75%

TMO Alerts

  • 1 major insider sales recently.

TMO Stock Price

TMO RSI Chart

TMO Valuation

Market Cap

191.4B

Price/Earnings (Trailing)

33.42

Price/Sales (Trailing)

4.4

EV/EBITDA

26.32

Price/Free Cashflow

32.69

TMO Price/Sales (Trailing)

TMO Profitability

EBT Margin

15.20%

Return on Equity

14.27%

Return on Assets

6.37%

Free Cashflow Yield

3.06%

TMO Fundamentals

TMO Revenue

Revenue (TTM)

43.5B

Revenue Y/Y

-2.58%

Revenue Q/Q

-0.21%

TMO Earnings

Earnings (TTM)

5.7B

Earnings Y/Y

-18.35%

Earnings Q/Q

5.42%

Price Action

52 Week Range

475.77609.85
(Low)(High)

Last 7 days

-1.9%

Last 30 days

-11.0%

Last 90 days

-4.5%

Trailing 12 Months

-2.2%

TMO Financial Health

Current Ratio

1.27

Debt/Equity

0.69

Debt/Cashflow

0.26

TMO Investor Care

Dividend Yield

0.26%

Dividend/Share (TTM)

1.3

Buy Backs (1Y)

1.53%

Diluted EPS (TTM)

14.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for TMO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-30
Pettiti Gianluca
acquired
761,970
253
3,000
executive vice president
2023-08-30
Pettiti Gianluca
sold
-1,673,310
557
-3,000
executive vice president
2023-08-28
Williamson Stephen
sold (taxes)
-157,633
545
-289
sr. vp and cfo
2023-08-28
Holmes Joseph R.
sold (taxes)
-6,721
545
-12.328
vp & chief accounting officer
2023-08-28
CASPER MARC N
sold (taxes)
-509,274
545
-934
chairman & ceo
2023-08-28
Boxer Michael A
sold (taxes)
-56,675
545
-103
svp and general counsel
2023-08-28
Lagarde Michel
sold (taxes)
-190,846
545
-350
executive vice president & coo
2023-08-28
Britt Lisa P.
sold (taxes)
-60,891
545
-111
sr. vp and chief hr officer
2023-08-28
Pettiti Gianluca
sold (taxes)
-148,671
545
-272
executive vice president
2023-08-25
Pettiti Gianluca
sold (taxes)
-204,250
541
-377
executive vice president

1–10 of 50

Which funds bought or sold TMO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-31.58
-389,021
632,883
-%
2023-09-26
DecisionPoint Financial, LLC
sold off
-100
-11,528
-
-%
2023-09-26
M Holdings Securities, Inc.
sold off
-100
-549,000
-
-%
2023-09-21
Jefferies Group LLC
added
23.6
3,292,640
24,694,100
0.21%
2023-09-21
Baystate Wealth Management LLC
added
214
108,668
167,742
0.01%
2023-09-21
Halpern Financial, Inc.
new
-
6,522
6,522
-%
2023-09-20
BARCLAYS PLC
added
39.22
126,910,000
614,468,000
0.39%
2023-09-14
IMS Capital Management
added
2.02
-54,466
657,927
0.36%
2023-09-13
CGC Financial Services, LLC
new
-
188,352
188,352
0.12%
2023-09-12
Farther Finance Advisors, LLC
added
28.16
83,248
603,291
0.13%

1–10 of 44

Latest Funds Activity

Are funds buying TMO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TMO
No. of Funds

Schedule 13G FIlings of Thermo Fisher Scientific

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.30%
32,534,676
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
30,790,122
SC 13G/A
Feb 10, 2022
vanguard group inc
7.89%
31,103,788
SC 13G/A
Feb 01, 2022
blackrock inc.
7.9%
30,982,611
SC 13G
Feb 10, 2021
vanguard group inc
7.82%
30,997,381
SC 13G/A
Feb 01, 2021
blackrock inc.
7.4%
29,504,221
SC 13G/A
Feb 12, 2020
vanguard group inc
7.77%
31,187,697
SC 13G/A
Feb 06, 2020
blackrock inc.
7.0%
28,202,856
SC 13G/A

Recent SEC filings of Thermo Fisher Scientific

View All Filings
Date Filed Form Type Document
Sep 21, 2023
8-K/A
Current Report
Aug 31, 2023
4
Insider Trading
Aug 30, 2023
144
Notice of Insider Sale Intent
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading
Aug 29, 2023
4
Insider Trading

TMO Fair Value

Loading...

Peers (Alternatives to Thermo Fisher Scientific)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
191.4B
43.5B
-11.02% -2.25%
33.42
4.4
1.64% -23.14%
23.8B
4.0B
-11.06% 0.30%
26.75
6.01
2.30% 16.37%
21.6B
4.5B
-19.01% -28.49%
-5.15
4.83
-4.92% -21931.58%
16.0B
3.0B
-3.74% 0.37%
23.68
5.34
3.16% -3.93%
9.1B
2.7B
-5.72% 17.17%
28.6
3.36
9.64% 16.50%
MID-CAP
1.5B
551.6M
-21.56% 38.21%
-13.2
2.74
12.73% 21.90%
SMALL-CAP
2.0B
146.1M
-29.45% 38.67%
-6.32
13.8
4.72% -55.19%
1.0B
112.0M
-0.96% 142.38%
-15.25
8.96
0.83% 16.42%
750.7M
189.6M
-23.79% -27.11%
-3.93
3.96
18.74% 17.75%
267.6M
37.3M
-25.86% -1.39%
-2.53
7.17
-9.96% -38.49%
181.9M
114.1M
-3.40% 66.41%
-33.5
1.59
-5.49% -48.58%
138.2M
99.2M
10.00% -67.33%
-2.44
1.39
-26.56% -199.52%
109.3M
80.9M
-6.41% 18.70%
-16.83
1.35
17.20% 77.07%
97.4M
31.5M
-23.90% 60.11%
-0.66
3.09
35.12% -38.47%

Thermo Fisher Scientific News

InvestorsObserver
Is Thermo Fisher Scientific Inc (TMO) a Good Buy in the Healthcare Sector?.
InvestorsObserver,
109 minutes ago
Marketscreener.com
Yahoo Finance
13 Best Robotics Stocks To Buy Now.
Yahoo Finance,
4 days ago
Zacks Investment Research

Returns for TMO

Cumulative Returns on TMO

18.6%


10-Year Cumulative Returns

17.9%


7-Year Cumulative Returns

15.1%


5-Year Cumulative Returns

4.5%


3-Year Cumulative Returns

Risks for TMO

What is the probability of a big loss on TMO?

16.1%


Probability that Thermo Fisher Scientific stock will be more than 20% underwater in next one year

0%


Probability that Thermo Fisher Scientific stock will be more than 30% underwater in next one year.

0%


Probability that Thermo Fisher Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TMO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.

Drawdowns

Financials for Thermo Fisher Scientific

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.6%43,52443,80744,91544,16742,82041,12339,21139,05938,25035,89432,21828,49726,24825,64725,54225,22024,86824,63024,35823,89823,094
Costs and Expenses0.4%36,81236,67236,52235,09733,18231,32329,18328,49827,54125,95724,42422,54221,77321,06720,94820,71020,39220,71320,57520,30619,780
  S&GA Expenses-0.7%8,7718,8358,9938,9728,7688,4588,0077,8067,3947,2056,9306,3656,3126,1676,1446,1426,0936,0706,0576,0265,936
  R&D Expenses-1.4%1,4331,4531,4711,4721,4721,4501,4061,3901,3351,2561,1811,0671,0181,0001,003992985981967949926
EBITDA-100.0%-8,5379,5479,4859,97910,05810,20811,19111,24211,96910,0458,1876,7776,9617,0137,0237,0396,4686,1965,9455,569
EBITDA Margin-100.0%-0.19*0.21*0.21*0.23*0.24*0.26*0.29*0.29*0.33*0.31*0.29*0.26*0.27*0.27*0.28*0.28*0.26*0.25*0.25*0.24*
Interest Expenses20.0%1,068890726618573547536521537552553549569613676712740756667--
Earnings Before Taxes-7.3%6,1716,6587,8357,9208,4968,6288,8419,8769,9519,1557,2305,3733,9434,0834,0724,0444,0323,4453,2623,0702,740
EBT Margin-100.0%-0.15*0.17*0.18*0.20*0.21*0.23*0.25*0.26*0.25*0.22*0.19*0.15*0.16*0.16*0.16*0.16*0.14*0.13*0.13*0.12*
Net Income-5.1%5,7266,0326,9607,0457,4507,6117,7288,5698,5997,9266,3774,8793,7063,6693,6963,5923,5413,1742,9382,5682,393
Net Income Margin-100.0%-0.14*0.15*0.16*0.17*0.19*0.20*0.22*0.22*0.22*0.20*0.17*0.14*0.14*0.14*0.14*0.14*0.13*0.12*0.11*0.10*
Free Cashflow-100.0%-5,6206,9115,6006,3367,0016,7897,9168,1328,0626,8155,6864,2453,7024,0473,9404,0864,2733,7853,9193,690
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.6%94,10594,65897,15490,53690,57992,74795,12373,60067,69865,93169,05264,06161,59358,68858,38156,72957,97055,59656,23255,07855,403
  Current Assets-1.1%19,99520,20925,22919,29918,10018,77620,11324,72419,26017,68521,95718,23415,77512,73811,89310,51411,2239,93910,6259,5669,474
    Cash Equivalents-10.0%3,1333,4828,5242,9191,9052,7794,49112,0487,0355,60310,3367,5705,8373,0102,4221,3052,3141,1282,1171,111956
  Inventory-0.2%5,6555,6645,6345,7225,6685,4835,0514,9064,6254,3424,0293,8293,6483,4543,3703,3083,2093,1243,0052,9822,866
  Net PPE-0.7%9,2929,3549,2808,6288,5298,4488,3337,0496,5606,1335,9125,1804,8874,7364,7494,4204,3944,1924,1653,9783,952
  Goodwill0.3%43,27343,14041,19640,48841,06641,72141,92426,90926,90426,82326,04125,78225,70025,61425,71425,62425,75725,23625,34725,14225,120
  Current Liabilities-11.2%14,11215,88417,01011,11810,99712,07013,4367,7536,9256,99510,3046,2286,0135,5006,1975,8447,5095,8986,1475,1965,980
  Long Term Debt0.2%29,19429,13528,90928,15029,25031,38932,33321,688--19,107-----16,66316,81217,71917,76017,709
    LT Debt, Non Current---------18,77318,64119,10721,09120,63819,23117,07616,392--17,719--
Shareholder's Equity3.4%43,75242,31043,97843,54942,35441,01840,85538,75736,90135,06834,51731,82429,87528,55929,68429,35528,72927,69327,59426,89026,445
  Retained Earnings2.8%44,28943,06441,91040,45239,07437,52835,43133,87632,07630,35028,11625,70523,86022,79122,09221,16520,48219,43918,70017,86617,226
  Additional Paid-In Capital0.8%17,03016,88916,74316,59616,46716,29216,17415,96015,82615,68415,57915,46715,33415,18615,06414,96414,88714,77114,62114,52614,408
Shares Outstanding0%386386-392392392-394393394-396395397-401400400-402403
Minority Interest-5.7%50.0053.0054.0059.0061.0062.0062.00---10.00----------
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations0.2%7,6937,6819,1548,1248,8379,5369,31210,19410,2529,9118,2896,8635,2724,6804,9734,8614,9645,1144,5434,6084,317
  Share Based Compensation-1.0%302305307309283257230204205201196188178183181182186182181180179
Cashflow From Investing-0.5%-4,655-4,631-2,159-20,326-20,397-20,604-21,932-3,866-3,615-3,248-1,510-1,223-1,056-1,566-1,487-1,869-1,839-1,255-1,253-815-7,616
Cashflow From Financing19.9%-1,809-2,258-2,8103,2666,4578,2866,581-1,935-5,766-4,510959494-584-1,074-3,118-2,617-1,624-3,320-2,237-3,3683,589
  Dividend Payments3.8%487469455441425411395379364348337326316305297289281274266258248
  Buy Backs0%4,0004,0003,0002,0002,0002,0002,0002,0002,0002,0001,5002,2502,2502,2501,5001,0001,2501,250500250-

TMO Income Statement

2023-07-01
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jul. 01, 2023
Jul. 02, 2022
Jul. 01, 2023
Jul. 02, 2022
Revenues    
Revenues$ 10,687$ 10,970$ 21,397$ 22,788
Costs and operating expenses:    
Selling, general and administrative expenses2,1452,2094,2644,486
Research and development expenses345365691729
Restructuring and other costs1832429526
Total costs and operating expenses9,1098,96918,25617,966
Operating income1,5782,0013,1414,822
Interest income1783632454
Interest expense(326)(148)(626)(284)
Other income/(expense)028(46)(135)
Income before income taxes1,4301,9172,7934,457
Provision for income taxes(52)(198)(98)(499)
Equity in earnings/(losses) of unconsolidated entities(16)(51)(41)(70)
Net income1,3621,6682,6543,888
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest1449
Net income attributable to Thermo Fisher Scientific Inc.$ 1,361$ 1,664$ 2,650$ 3,879
Earnings per share attributable to Thermo Fisher Scientific Inc.    
Basic (in dollars per share)$ 3.53$ 4.25$ 6.86$ 9.90
Diluted (in dollars per share)$ 3.51$ 4.22$ 6.83$ 9.83
Weighted average shares    
Basic (in shares)386392386392
Diluted (in shares)388394388394
Product revenues    
Revenues    
Revenues$ 6,271$ 7,003$ 12,675$ 15,020
Costs and operating expenses:    
Cost of revenues3,2783,5166,6157,071
Service revenues    
Revenues    
Revenues4,4163,9678,7227,768
Costs and operating expenses:    
Cost of revenues$ 3,158$ 2,855$ 6,391$ 5,654

TMO Balance Sheet

2023-07-01
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jul. 01, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 3,133$ 8,524
Accounts receivable, less allowances of $180 and $1898,0198,115
Inventories5,6555,634
Contract assets, net1,4671,312
Other current assets1,7211,644
Total current assets19,99525,229
Property, plant and equipment, net9,2929,280
Acquisition-related intangible assets, net17,43717,442
Other assets4,1084,007
Goodwill43,27341,196
Total assets94,10597,154
Current liabilities:  
Short-term obligations and current maturities of long-term obligations4,8145,579
Accounts payable2,4233,381
Accrued payroll and employee benefits1,3102,095
Contract liabilities2,5902,601
Other accrued expenses2,9753,354
Total current liabilities14,11217,010
Deferred income taxes2,8422,849
Other long-term liabilities4,0424,238
Long-term obligations29,19428,909
Redeemable noncontrolling interest113116
Thermo Fisher Scientific Inc. shareholders’ equity:  
Preferred stock, $100 par value, 50,000 shares authorized; none issued00
Common stock, $1 par value, 1,200,000,000 shares authorized; 441,398,059 and 440,668,112 shares issued441441
Capital in excess of par value17,03016,743
Retained earnings44,28941,910
Treasury stock at cost, 55,448,286 and 50,157,275 shares(15,084)(12,017)
Accumulated other comprehensive income/(loss)(2,924)(3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity43,75243,978
Noncontrolling interests5054
Total equity43,80244,032
Total liabilities, redeemable noncontrolling interest and equity$ 94,105$ 97,154
Marc N. Casper
65535
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.